We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
B-cell Non-Hodgkin's Lymphoma Refractory is a type of cancer that affects the lymphatic system, specifically the B-cells, and does not respond to standard treatments. Patients may experience symptoms such as swollen lymph nodes, fever, night sweats, and unexplained weight loss.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
